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Although microRNAs (miRNAs) are involved in many biological processes, the mechanisms whereby
miRNAs regulate osteoblastic differentiation are poorly understood. Here, we found that BMP-4-
induced osteoblastic differentiation of bone marrow-derived ST2 stromal cells was promoted and
repressed after transfection of sense and antisense miR-210, respectively. A reporter assay demon-
strated that the activin A receptor type 1B (AcvR1b) gene was a target for miR-210. Furthermore,
inhibition of transforming growth factor-b (TGF-b)/activin signaling in ST2 cells with SB431542 pro-
moted osteoblastic differentiation. We conclude that miR-210 acts as a positive regulator of osteo-
blastic differentiation by inhibiting the TGF-b/activin signaling pathway through inhibition of
AcvR1b.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are classiﬁed as regulatory RNAs, and
have been reported to play important roles in the development,
proliferation and differentiation of various types of cells. Among
the various miRNAs, miR-143 regulates adipocyte differentiation,
miR-206 regulates muscle differentiation and miR-133 regulates
skeletal differentiation [1–3]. miR-223 regulates granulopoiesis
by a feedback mechanism and is modulated competitively by the
transcription factors nuclear factor I/A (NFI-A) and CCAAT/enhan-
cer binding protein-a (C/EBPa) [4]. miR-223 was also recently re-
ported to regulate osteoclastogenesis in RAW 264.7 cells [5].
Some miRNAs are known to be present in cancer cells and act as
oncogenes or tumor suppressor genes [6–8]. miR-21 has beenchemical Societies. Published by E
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tory.reported to be an oncogene that promotes tumor growth by down-
regulating the tropomyosin 1 tumor suppressor (TPM1) gene
[9,10]. Expression of miR-17 is regulated by the myelocytomatosis
(c-Myc) oncogene and acts as an oncogene by regulating cell pro-
liferation through E2F transcription factor 1 (E2F1) [11,12]. On
the other hand, the let-7 miRNA suppresses the high mobility
group AT-hook 2 (HMGA2) oncogene and acts as a tumor suppres-
sor gene [13]. The let-7 miRNA is also known to suppress cell pro-
liferation [14] and induce regression of colon cancer [15].
Although miRNAs are known to play a number of regulatory
roles, little is known about their roles in osteoblastic differentia-
tion. As a functional miRNA, we recently reported that miR-125b
negatively regulates osteoblastic differentiation by mediating cell
proliferation [16]. However, there are no reports of miRNAs that
positively regulate osteoblastic differentiation.
In the present study, we demonstrate positive regulation of
osteoblastic differentiation by miR-210. The expression proﬁles
of miRNAs during osteoblastic differentiation of mouse ST2 mes-
enchymal stem cells were obtained by miRNA microarray analy-
ses, and miR-210 was found to be highly expressed in these
cells. Quantitative reverse transcription-polymerase chain reac-
tion (qRT-PCR) conﬁrmed that miR-210 expression was upregu-
lated during osteoblastic differentiation. We also analyzed the
function of miR-210 in osteoblastic differentiation by transfectionlsevier B.V. All rights reserved.
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miRNA target gene databases MiRanda and TargetScan predicted
that the activin A receptor type 1B (AcvR1b; also known as
Alk4) gene could be a target for miR-210. The regulatory relation-
ship between miR-210 and AcvR1b was conﬁrmed by reporter as-
says. The role of transforming growth factor-b (TGF-b)/activin
signaling for osteoblastic differentiation in ST2 cells was also
validated.2. Materials and methods
2.1. Cell culture
ST2 cells and NRG cells were obtained from the RIKEN BioRe-
source Center (BRC, Tsukuba, Japan) and cultured according to
the supplier’s protocols using RPMI-1640 medium and DMEM,
respectively, supplemented with 10% fetal bovine serum (FBS).
2.2. Osteoblastic differentiation
Osteoblastic differentiation was induced by replacing the med-
ium with fresh medium containing 10% FBS and 100 ng/ml of bone
morphogenetic protein-4 (BMP-4) (R&D Systems, Minneapolis,
MN) every third day. SB431542 (1 lM; Sigma, St. Louis, MO) was
added to fresh medium containing the above components for inhi-
bition of TGF-b/activin signaling.
2.3. miRNA microarray analysis
Small RNA fractions of total RNA were puriﬁed using a ﬂash-
PAGE Fractionator System (Ambion, Austin, TX) and labeled with
a mirVana miRNA Labeling Kit (Ambion), followed by loading on
a custom-made miRNA array on which a mirVana miRNA Probe
Set (Ambion) was printed according to the manufacturer’s instruc-
tions. After 16 h of hybridization, the signals were detected by a
microarray scanner (G2565BA; Agilent Technologies, Santa Clara,
CA) and quantiﬁed by the software Feature Extraction ver. 8.1 (Agi-
lent Technologies).
2.4. Alkaline phosphatase (ALP) staining and its measurement
Cells were ﬁxed with 10% formalin for 20 min, followed by ﬁx-
ation for 1 min in an ice-cold solution of equal volumes of ethanol
and acetone, and then washed with phosphate-buffered saline. The
ALP staining solution was prepared by dissolving 1 mg of Naphthol
AS-MX (Sigma) in one droplet of N,N-dimethylformamide (Wako,
Osaka, Japan) and suspending the droplet in 10 ml of 0.1 M Tris–
HCl buffer (pH 8.5) containing 2 mMMgCl2. Six micrograms of Fast
Blue BB salt (Sigma) was added and the ALP staining solution was
ﬁltered. The ﬁxed cells were incubated in the ALP staining solution
at 37 C for 20 min. A p-Nitrophenyl Phosphate Liquid Substrate
System (Sigma) was added to determine the ALP activity and the
absorbances at 405 nm were measured using an ARVO MX plate
reader (Perkin–Elmer, Norwalk, CT). ALP staining and ALP activity
measurements were performed in triplicate wells in two indepen-
dent experiments.
2.5. Cell proliferation assay
After plating cells and changing to fresh media containing
100 ng/ml BMP-4 and 10% FBS, the total cell count was measured
every day for 6 days using a CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega, Madison, WI) according to the
manufacturer’s instructions. The absorbances at 490 nm weremeasured with an ARVO MX plate reader (Perkin–Elmer). Back-
ground absorbances from empty wells were subtracted from those
of the sample wells.
2.6. qRT-PCR
Total RNA was isolated from cultured cells using a Nucleospin
column (Machery Nagel, Düren, Germany), according to the manu-
facturer’s instructions. A mirVana miRNA Isolation Kit (Applied
Biosystems, Forster City, CA) was used for puriﬁcation of miRNAs.
The yield and quality of the RNA samples were determined using a
NanoDrop spectrometer (NanoDrop Technology, San Diego, CA).
The expression levels were measured by qRT-PCR. Total RNA was
reverse-transcribed by Transcriptor (Roche, Mannheim, Germany)
with oligo-dT primers or speciﬁc primers for miR-210 (Applied
Biosystems) according to the manufacturer’s instructions. Using
the resulting cDNAs as templates, the gene expression levels were
measured using an Mx3000P system (Stratagene, La Jolla, CA) and
Power SYBR Green PCR Master Mix (Applied Biosystems) according
to the manufacturer’s instructions. The primer sequences for mea-
surement of mRNA expression were: 50-TGGAGAAACCTGCCAAG-
TATG-30 (glyceraldehyde phosphate dehydrogenase (GAPDH)-
forward); 50-GGAGACAACCTGGTCCTCAG-30 (GAPDH-reverse); 50-
CTCTGTCTCTCTGACCTCACAG-30 (osteocalcin (OC)-forward); 50-
GGAGCTGCTGTGACATCCATAC-30 (OC-reverse); 50-CGTCCTCTCTG
CTTGAGGAA-30 (Osterix-forward); 50-TTCCCCAGGGTTGTTGAGT-30
(Osterix-reverse); 50-AACGAGATCGAGCTCAGAGG-30 (Col1a1-for-
ward); 50-GGGAGGTCTTGGTGGTTTTG-30 (Col1a1-reverse); 50-CTG
GCTACAAGGTGGTGGAC-30 (ALP-forward); 50-GTCTTCTCCACC
GTGGGTCT-30 (ALP-reverse); 50-GCTTGGCTTATGGACTGAGG-30
(Osteopontin-forward); 50-CGCTCTTCATGTGAGAGGTG-30 (Osteo-
pontin-reverse); 50-GAGGGCACAAGTTCTATCTG-30 (Runx2-for-
ward); 50-GCTCGGATCCCAAAAGAAG-30 (Runx2-reverse). Speciﬁc
primers for miR-210 and U6 (Applied Biosystems) were used for
measurement of miRNA expression.2.7. Transfection
The sense strand of miR-210 (miR-210) and the antisense
strand of miR-210 (anti-miR-210) (Applied Biosystems) were used
to promote and inhibit miR-210 activity, respectively. Negative
controls were used for both reactions. For transfection, Lipofect-
amine 2000 (Invitrogen Corp., Carlsbad, CA) was mixed with
20 nM of the above-mentioned RNAs according to the manufac-
turer0s instructions, and these solutions were directly mixed with
ST2 cells in 24-well culture plates at a density of 3.2  104 cells/
well. For osteoblastic differentiation, the medium was replaced
with fresh medium containing 10% FBS and 100 ng/ml of BMP-4
at 4 h after transfection.2.8. Luciferase reporter assay
The miR-210 target region of the AcvR1b sequence (50-ATT-
CTCCAGACTCAAACGCACAT-30, part of the NCBI RefSeq ID of
NM_007395) or its mutated sequence (50-ATTCTCCAGAACCAA
CTATGTCT-30) was inserted downstream of the pGL4.13 luciferase
plasmid (Promega) and the resulting constructs were named
pGL4.13-AcvR1b and pGL4.13-AcvR1-mut, respectively. Cotrans-
fection of 200 ng of pGL4.13-AcvR1b or pGL4.13-AcvR1-mut with
20 nM miR-210 or anti-miR-210 was carried out in 24-well plates.
A native pGL4.13 luciferase plasmid was cotransfected with the
same concentration of miR-210 or anti-miR-210 in separate wells
as a control. Twenty nanograms of a Renilla luciferase vector,
pGL4.74 (Promega), was also transfected into all samples for
Table 1
miRNAs whose expression are changed during osteoblastic differentiation (day 14)
comparing to Control (without BMP-4) (1 day).
miRNA log 2 ratio (B14/C1)
Upregulated
let-7d 2.97
let-7a-1 2.72
miR-210 2.20
let-7f-2 2.16
let-7f-1 1.79
miR-16-1 1.65
let-7b 1.55
Downregulated
miR-329 4.31
miR-122a 2.01
miR-23a 1.12
miR-147 1.04
miR-198 1.01
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tions were repeated three times. After 48 h, the cells were har-
vested with PLB reagent (Promega) and the ﬁreﬂy luciferase
activity was measured in each well using the LARII substrate and
a Dual Luciferase Assay Kit (Promega) with the ARVO MX plate
reader. The relative ﬁreﬂy luciferase activity was calculated by nor-
malization to the Renilla luciferase activity.Fig. 1. Relative expression of endogenous miR-210 during osteoblastic differentiation o
100 ng/ml. Control cells were cultured without BMP-4. Cells were harvested at 2, 6 and
expression at each time point with and without the addition of BMP-4 compared with d
with and without BMP-4, respectively. Asterisks indicate signiﬁcant t-test results (P < 0.
days, and the expression levels of miR-210 was measured by qRT-PCR. (C and D) Chara
differentiation of ST2 cells. BMP-4 was added at a concentration of 100 ng/ml, then cell
were performed. Solid squares and white triangles indicate cultures with and without B3. Results
3.1. Expression of miR-210 is upregulated during osteoblastic
differentiation
To elucidate the differential expression of miRNAs during osteo-
blastic differentiation, a microarray analysis for miRNAs was per-
formed. We found that the expressions of several miRNAs
changed during osteoblastic differentiation (Table 1). Several let-
7 family miRNAs, miR-210 and miR-16-1 were listed as upregu-
lated. The let-7 family miRNAs are known to be broadly expressed
in many different cells and tissues, and have several known func-
tions. In contrast, the function of miR-210 has been poorly under-
stood to date. Therefore, we focused on the possibility of a
regulatory role for miR-210 in osteoblastic differentiation. qRT-
PCR with the miRNA measurement protocol was performed to fur-
ther analyze the expression pattern of miR-210 during osteoblastic
differentiation of ST2 cells. As shown in Fig. 1A, miR-210 expres-
sion was greatly upregulated at day 12 when ST2 cells were cul-
tured with BMP-4, suggesting its involvement in osteoblastic
differentiation of ST2 cells. To test whether the increase in miR-
210 was a dose-responsive effect to BMP-4, increasing amounts
of BMP-4 were introduced for osteoblastic differentiation. The
expression level of miR-210 increased until the BMP-4 concentra-
tion reached 50 ng/ml (Fig. 1B), indicating that the induction off ST2 cells. (A) After plating ST2 cells, BMP-4 was added at a ﬁnal concentration of
12 days after the addition of BMP-4, and the relative levels of endogenous miR-210
ay 0 were measured by qRT-PCR. Solid bars and white bars indicate cells incubated
01). (B) BMP-4 was added in increasing amounts (25, 50, 100 and 250 ng/ml) for 6
cterization of cell proliferation and osteocalcin (OC) expression during osteoblastic
proliferation assays (C) and measurement of osteocalcin expression by qRT-PCR (D)
MP-4, respectively.
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proﬁles of cell proliferation and the expression levels of the osteo-
blastic marker OC, cell proliferation assays and qRT-PCR were per-
formed, respectively. We found that proliferation stopped at 2–3
days after osteoblastic differentiation (Fig. 1C), and that the
expression of OC began to increase at 4 days after osteoblastic dif-
ferentiation (Fig. 1D).
3.2. Transfection of miR-210 promotes osteoblastic differentiation of
ST2 cells
To determine whether miR-210 could inﬂuence osteoblastic dif-
ferentiation, miR-210 and anti-miR-210 were individually trans-
fected into ST2 cells and their effects were assessed by observing
the ALP activity and expression level of OC transcripts. ALP staining
and activity were increased following transfection of miR-210
compared with transfection of control RNA (Fig. 2A and B). OC
expression was also increased following miR-210 transfection
(Fig. 2C), suggesting that stimulation of miR-210 activity promoted
osteoblastic differentiation of ST2 cells. By contrast, transfection of
anti-miR-210 reduced the expression of OC (Fig. 2C). The expres-
sion levels of other osteoblastic markers, namely osterix and ALP,
were also upregulated following transfection with miR-210
(Fig. 2D). These results indicate that miR-210 positively regulates
the osteoblastic differentiation of ST2 cells. To examine whether
the regulation of osteoblastic differentiation by miR-210 occurs
in other osteoblast-like cells, similar experiments were performed
using the mouse NRG cell line. We used this cell line because
osteoblastic differentiation can be induced at a lower concentra-Fig. 2. Inﬂuences of transfections with miR-210 and anti-miR-210 on osteoblastic differe
(NC) RNA were transfected into ST2 cells and BMP-4 was added 4 h later. ALP staining w
values. (C) The relative expression of OC transcripts was measured after 5 days. (D) qRT-P
osteoblastic differentiation was induced by BMP-4. Osx: osterix; Col1a1: collagen, type 1
NRG cells in which osteoblastic differentiation was induced by BMP-4 at 25 ng/ml for 4
days. Asterisks indicate signiﬁcant t-test results (P < 0.05).tion of BMP-4 and within a shorter period compared with the
ST2 cell line. As shown in Fig. 2E, the level of ALP activity was ele-
vated when miR-210 was transfected into NRG cells, as observed in
ST2 cells, indicating that the promotion of osteoblastic differentia-
tion by miR-210 is not restricted to the ST2 cell line.
3.3. AcvR1b is a target of miR-210
More than 200 genes were predicted by PicTar or TargetScan to
be potential target genes for miR-210 [17,18]. We focused on
AcvR1b (Fig. 3A), which is a member of the BMP receptor family.
In this family, activin-like kinase 2 (Alk2) is known to regulate
BMP signal transduction, whereas AcvR1b regulates the TGF-
b/activin signaling pathway [19]. We used a luciferase reporter
assay system and transfection of sense and antisense strands of
miR-210 to determine whether AcvR1b was a target for miR-210,
and to investigate its effects on osteoblastic differentiation. To test
whether the predicted target sequence in the AcvR1b gene was reg-
ulated by miR-210, we cloned the predicted target sequence down-
stream of the luciferase reporter gene and cotransfected it with
miR-210 or anti-miR-210. The relative luciferase activity was re-
duced by 50% following cotransfection with miR-210 compared
with transfection with control RNA (Fig. 3B). By contrast, transfec-
tion with anti-miR-210 slightly increased the luciferase activity,
although the difference was not statistically signiﬁcant. When
the targeted sequence of AcvR1b was mutated, the reduction of
the luciferase activity by miR-210 was impaired (Fig. 3C). These re-
sults suggest that miR-210 targets the predicted site in the AcvR1b
gene.ntiation of ST2 cells. miR-210 (sense), anti-miR-210 (antisense) or a negative control
as performed (A) and the ALP activity was measured (B), and compared with the NC
CR analysis of other bone markers than OC in miR-210-transfected ST2 cells in which
, alpha 1; OP: osteopontin. (E) Measurement of ALP activity in miR-210-transfected
days. Each experiment was performed in triplicate wells and on two independent
Fig. 3. Evaluation of targeting of AcvR1b by miR-210. (A) The region of the mouse AcvR1b mRNA 30 UTR predicted to be targeted by miR-210 (TargetScan 4.1). (B and C) The
relative activity of the luciferase reporter of the target sequence of miR-210 in the AcvR1b 30 UTR after cotransfection of sense or antisense miR-210, compared with the
transfection of a negative control (NC) RNA. Part of the AcvR1b 30 UTR (the predicted target sequence for miR-210) (B) or its mutated sequence (C) was cloned into a luciferase
vector and cotransfected with miR-210, anti-miR-210 or an NC RNA. The luciferase activity was measured at 2 days after transfection. Solid bars indicate transfection of miR-
210 or anti-miR-210, and white bars indicate transfection of the NC miRNA. Asterisks indicate signiﬁcant t-test results (P < 0.05).
Y. Mizuno et al. / FEBS Letters 583 (2009) 2263–2268 22673.4. Inhibition of AcvR1b by SB431542 promotes osteoblastic
differentiation of ST2 cells
To further elucidate whether miR-210 promotes osteoblastic
differentiation by inhibiting the signaling pathway of AcvR1b, we
tried to use the chemical SB431542, which is a speciﬁc inhibitor
for receptors of TGF-b/activin signaling [19,20]. Following addition
of SB431542, ALP activity and OC expression were both elevated
(Fig. 4A and B). These results suggest that osteoblastic differentia-
tion of ST2 cells is promoted by downregulation of the TGF-b/acti-
vin signaling pathway. Taken together, the inhibition of TGF-b/
activin signaling by either miR-210 or SB431542 promotes osteo-
blastic differentiation of ST2 cells.Fig. 4. Inhibition of TGF-b/activin signaling by SB431542 promotes osteoblastic
differentiation. The culture medium was changed to fresh medium containing
SB431542, an inhibitor of TGF-b/activin signaling, at 4 h and 3 days after plating of
ST2 cells. The relative ALP activity (A) and relative expression of OC transcripts (B)
compared with mock vector treatment were measured on day 6. Solid and white
bars indicate cultures with and without SB431542, respectively. Asterisks indicate
signiﬁcant t-test results (P < 0.05).4. Discussion
Osteoblastic differentiation of mesenchymal stem cells can be
strongly induced by BMPs [21]. The involvement of miRNAs in var-
ious cellular events suggests that they could also have a regulatory
function in osteoblast differentiation. However, the regulatory
mechanisms of miRNAs in osteoblast proliferation and differentia-
tion are currently poorly understood. We recently reported that
miR-125b downregulated osteoblastic differentiation through
inhibition of cell proliferation [16]. In that study, in vitro cell pro-
liferation was inhibited when miR-125b was transfected, and
osteoblastic differentiation was inhibited owing to the low density
of the differentiating cells. That study was the ﬁrst to demonstrate
a function of miRNAs in regulating osteoblastic differentiation.
miR-133 and miR-135 have subsequently been reported to inhibit
BMP-2-induced osteoblastic differentiation by directly targeting
the genes for Runx2 and Smad5 [22]. However, the miRNAs studied
to date all act as inhibitors of osteoblastic differentiation, and no
positive regulation by miRNAs has been reported.
The miRNA array data showed that miR-210 was upregulated
during osteoblastic differentiation. Furthermore, the present re-
sults showed that miR-210 positively regulated osteoblastic differ-
entiation of mouse mesenchymal ST2 cells. A recent study found
that miR-210 was induced by hypoxia and involved in cell cycle
regulation through targeting of E2F transcription factor 3 [23,24].
These results suggest that miR-210 could be involved in cell prolif-
eration in cancer and under hypoxic conditions. However, the ef-
fects of miR-210 on cell differentiation have not been reported.
The results of the present study indicate that miR-210 was able
to positively regulate osteoblastic differentiation via targeting of
the TGF-b/activin signaling pathway. AcvR1b is a type I receptor
which, together with the type II receptor ActRII, transmits signals
from activin. When activated, this receptor is known to transmit
signals to the receptor-regulated Smads (R-smad) Smad2 and 3,
but not Smad1, 5 or 8, through their phosphorylation, resulting
in the transcription of genes that function as inhibitory regulators
of proliferation. BMP signals, however, are transmitted via other
receptors, such as AcvR1 (Alk2), Bmpr1a (Alk3) and Bmpr1b
(Alk6) and their signals are transmitted to Smad1, 5 and 8, thereby
2268 Y. Mizuno et al. / FEBS Letters 583 (2009) 2263–2268initiating osteoblastic differentiation. It has been reported that
Smad2/3 and Smad1/5/8 signaling can interfere with each other
by competitive binding to a co-Smad, Smad4 [19]. Inhibition of
Smad2/3 signaling is known to activate Smad1/5/8 signaling,
resulting in acceleration of osteoblastic differentiation [19,20].
MiRanda and TargetScan both predicted that Acvr1b is a target
gene for miR-210 in mice and humans. Therefore, we considered
the possibility that the promotion of osteoblastic differentiation
associated with the stimulation of miR-210 activity arose through
its inhibition of AcvR1b. Regulation of the predicted 30 UTR region
of AcvR1b by miR-210 was demonstrated by luciferase reporter as-
says, and inhibition of AcvR1bwas associated with increased osteo-
blastic differentiation in our culture system using the ST2 bone
marrow-derived cell line. Thus the promotion of osteoblast differ-
entiation by miR-210 could be explained by inhibition of the TGF-
b/activin signaling pathway, through targeting of AcvR1b. Our re-
sults could provide an important step toward resolving bone disor-
ders, such as osteoporosis. Elucidation of the roles of miRNAs in
osteoblast regulation in vivo could help to clarify the mechanisms
of bone metabolism and turnover.Acknowledgments
We thank Mai Kitazato, Shino Okumura and Megumi Otsu for
their technical assistance. We also thank Yutaka Nakachi, Shigeki
Arai and Riki Kurokawa for their helpful discussions. This work
was supported by grants for the Genome Network Project from
the Ministry of Education, Culture, Sports, Science and Technology
(MEXT) of Japan to Y.O., and also in part by the Ministry of Educa-
tion, Culture, Sports, Science and Technology (MEXT) of Japan, and
in particular by a Ministry Grant to SaitamaMedical University, Re-
search Center for Genomic Medicine.References
[1] Esau, C., Kang, X., Peralta, E., Hanson, E., Marcusson, E.G., Ravichandran, L.V.,
et al. (2004) MicroRNA-143 regulates adipocyte differentiation. J. Biol. Chem.
279, 52361–52365.
[2] Kim, H.K., Lee, Y.S., Sivaprasad, U., Malhotra, A. and Dutta, A. (2005) Muscle-
speciﬁc microRNA miR-206 promotes muscle differentiation. J. Cell Biol. 174,
677–687.
[3] Chen, J.F., Mandel, E.M., Thomson, J.M., Wu, Q., Callis, T.E., Hammond, S.M.,
et al. (2006) The role of microRNA-1 and microRNA-133 in skeletal muscle
proliferation and differentiation. Nat. Genet. 38, 228–233.[4] Fazi, F., Rosa, A., Fatica, A., Gelmetti, V., De Marchis, M.L., Nervi, C., et al. (2005)
A minicircuitry comprised of microRNA-223 and transcription factors NFI-A
and C/EBPa regulates human granulopoiesis. Cell 123, 819–831.
[5] Sugatani, T. and Hruska, K.A. (2007) MicroRNA-223 is a key factor in osteoclast
differentiation. J. Cell Biochem. 101, 996–999.
[6] Hayashita, Y., Osada, H., Tatematsu, Y., Yamada, H., Yanagisawa, K., Tomida, S.,
et al. (2005) A polycistronic microRNA cluster, miR-17–92, is overexpressed in
human lung cancers and enhances cell proliferation. Cancer Res. 65, 9628–
9632.
[7] Zhang, B., Pan, X., Cobb, G.P. and Anderson, T.A. (2007) MicroRNAs as
oncogenes and tumor suppressors. Dev. Biol. 302, 1–12.
[8] Lee, Y.S. and Dutta, A. (2006) MicroRNAs: small but potent oncogenes or tumor
suppressors. Curr. Opin. Investig. Drugs 7, 560–564.
[9] Zhu, S., Si, M.L., Wu, H. and Mo, Y.Y. (2007) MicroRNA-21 targets the tumor
suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 282, 14328–14336.
[10] Si, M.L., Zhu, S., Wu, H., Lu, Z., Wu, F. and Mo, Y.Y. (2007) MiR-21-mediated
tumor growth. Oncogene 26, 2799–2803.
[11] O’Donnell, K.A., Wentzel, E.A., Zeller, K.I., Dang, C.V. and Mendell, J.T. (2005) C-
Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 839–843.
[12] Mendell, J.T. (2005) MicroRNAs: critical regulators of development, cellular
physiology and malignancy. Cell Cycle 4, 1179–1184.
[13] Lee, Y.S. and Dutta, A. (2007) The tumor suppressor microRNA let-7 represses
the HMGA2 oncogene. Genes Dev. 21, 1025–1030.
[14] Johnson, C.D., Esquela-Kerscher, A., Stefani, G., Byrom, M., Kelnar, K.,
Ovcharenko, D., et al. (2007) The let-7 microRNA represses cell proliferation
pathways in human cells. Cancer Res. 67, 7713–7722.
[15] Akao, Y., Nakagawa, Y. and Naoe, T. (2006) Let-7 microRNA functions as a
potential growth suppressor in human colon cancer cells. Biol. Pharm. Bull. 29,
903–906.
[16] Mizuno, Y., Yagi, K., Tokuzawa, Y., Kanesaki-Yatsuka, Y., Suda, T., Katagiri, T.,
et al. (2008) MiR-125b inhibits osteoblastic differentiation by down-
regulation of cell proliferation. Biochem. Biophys. Res. Commun. 368, 267–
272.
[17] Krek, A., Grün, D., Poy, M.N., Wolf, R., Rosenberg, L., Epstein, E.J., et al. (2005)
Combinatorial microRNA target predictions. Nat. Genet. 37, 495–500.
[18] Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P. and Burge, C.B. (2003)
Prediction of mammalian microRNA targets. Cell 115, 787–798.
[19] Miyazono, K., Maeda, S. and Imamura, T. (2005) BMP receptor signaling:
transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine
Growth Factor Rev. 16, 251–263.
[20] Maeda, S., Hayashi, M., Komiya, S., Imamura, T. and Miyazono, K. (2004)
Endogenous TGF-b signaling suppresses maturation of osteoblastic
mesenchymal cells. EMBO J. 23, 552–563.
[21] Yamaguchi, A., Komori, T. and Suda, T. (2000) Regulation of osteoblast
differentiation mediated by bone morphogenetic proteins, hedgehogs, and
Cbfa1. Endocr. Rev. 221, 393–411.
[22] Li, Z., Hassan, M.Q., Volinia, S., van Wijnen, A.J., Stein, J.L., Croce, C.M., et al.
(2008) A microRNA signature for a BMP2-induced osteoblast lineage
commitment program. Proc. Natl. Acad. Sci. USA 105, 13906–13911.
[23] Camps, C., Buffa, F.M., Colella, S., Moore, J., Sotiriou, C., Sheldon, H., et al. (2008)
Hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in
breast cancer. Clin. Cancer Res. 14, 1340–1348.
[24] Giannakakis, A., Sandaltzopoulos, R., Greshock, J., Liang, S., Huang, J.,
Hasegawa, K., et al. (2008) MiR-210 links hypoxia with cell cycle regulation
and is deleted in human epithelial ovarian cancer. Cancer Biol. Ther. 7, 255–
264.
